Welcome to LookChem.com Sign In|Join Free

CAS

  • or

50-67-9

Post Buying Request

50-67-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • High quality 3-(2-aminoethyl)indol-5-ol 50-67-9 with best price

    Cas No: 50-67-9

  • USD $ 300.0-300.0 / Kilogram

  • 1 Kilogram

  • 3000 Kilogram/Month

  • Kono Chem Co.,Ltd
  • Contact Supplier

50-67-9 Usage

Description

Serotonin is the baby boomer of neurotransmitters: It was identified in the late 1940s, its adolescence was troubled and turbulent, it made the drug scene in the 1960s, and it nearly died of an overdose in the early 1970s. At one point, the remark was made that serotonin doesn't do anything. On reaching its middle years, serotonin has matured and become an important topic of study, a household name, and more complicated than ever. Serotonin has been associated with, among other things, anxiety, depression, schizophrenia, drug abuse, sleep, dreaming, hallucinogenic activity, headache, cardiovascular disorders, and appetite control, and it is now dabbling in acupuncture and transcendental meditation. Serotonin was independently identified in the late 1940s by two groups of investigators: In the United States, it was called serotonin, whereas in Italy, it was called enteramine. Its total synthesis in the early 1950s confirmed that both substances were 5-hydroxytryptamine (5-HT ). Serotonin (5-HT ) was detected in numerous plant and animal species and, in the mid-1950s, was identified in the central nervous system (CNS) of animals. A neurotransmitter role was subsequently proposed for this substance. Later, 5-HT was implicated in a variety of central and peripheral physiologic actions. It seemed to be involved in vasoconstriction and vasodilation, regulation of body temperature, sleep, and hormonal regulation, and evidence suggested that it might be involved in depression. The structural similarity between 5-HT and the then recently discovered hallucinogenic agent (+)-lysergic acid diethylamide (LSD) intrigued investigators. This observation led to speculation that 5-HT might be involved in the mechanism of action of psychoactive substances and that it might play a seminal role in various mental disorders.

Uses

neurotransmitter

Definition

ChEBI: A primary amino compound that is the 5-hydroxy derivative of tryptamine.

Biological Functions

Serotonin (5-hydroxytryptamine, or 5HT) is present in the brain as well as in the periphery. In humans, about 90% of the total serotonin in the body is in enterochromaffin cells in the gastrointestinal tract; the remaining 10% occurs primarily in the platelets and brain. The physiological significance of the vast amounts of serotonin constantly synthesized and metabolized in the periphery still remains an enigma. Brain serotonin has been implicated as a potential neurotransmitter in the mediation of a wide variety of phenomena.

Clinical Use

Initially, serotonin was thought to be a sleep-promoting neurotransmitter or an “antiwaking” agent. The recognition of the numerous 5-HT receptor subtypes, often with unique anatomical distribution, has required that a more complex role for serotonin be developed. Current studies indicate that conditions for sleep are now met when the serotoninergic system becomes inactive. The serotonin agonists for the 5-HT1 (via the 5-HT1A and 5-HT1B types at the hypothalamic level), 5-HT2, and 5-HT3 receptors cause wakefulness and inhibit sleep. Blockade of the 5-HT2 receptors (e.g., the 5-HT2 antagonist ritanserin) results in increased NREM sleep and inhibition of REM sleep. It has been proposed that the 5-HT1A and 5- HT2 may be involved in sleep by regulation of sleep-promoting substances in the hypothalamus. With the development of newer and more selective ligands for use in studying the numerous serotonin receptor subtypes, a better understanding of the role of serotonin in sleep will evolve.

Metabolism

The major route of metabolism for 5-HT is oxidative deamination by monoamine oxidase (MAO-A) to the unstable 5-hydroxyindole- 3-acetaldehyde, which is either reduced to 5-hydroxytryptophol (~15%) or oxidized to 5-hydroxyindole-3-acetic acid (~85%). In the pineal gland, 5-HT is acetylated by 5-HT N-acetyltransferase to N-acetylserotonin, which undergoes O-methylation by 5-hydroxyindole-O-methyltransferase to melatonin.

References

Petrova, Men'shikov,J. Gen. Chern. USSR, 31,2413 (1961)

Check Digit Verification of cas no

The CAS Registry Mumber 50-67-9 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 0 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 50-67:
(4*5)+(3*0)+(2*6)+(1*7)=39
39 % 10 = 9
So 50-67-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O/c11-4-3-7-6-12-10-2-1-8(13)5-9(7)10/h1-2,5-6,12-13H,3-4,11H2

50-67-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name Serotonin

1.2 Other means of identification

Product number -
Other names Indol-5-ol, 3-(2-aminoethyl)-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:50-67-9 SDS

50-67-9Synthetic route

N-Benzyl-2-<5-(benzyloxy)-3-indolyl>-1-ethanamin
147918-24-9

N-Benzyl-2-<5-(benzyloxy)-3-indolyl>-1-ethanamin

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With palladium 10% on activated carbon; ammonium formate In methanol at 70℃; for 0.75h; Inert atmosphere;100%
L-5-HTP
4350-09-8

L-5-HTP

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With pyridoxal 5'-phosphate; aromatic L-amino acid decarboxylase In various solvent(s) at 30℃; for 48h;97%
With NH4OH-NH4Cl buffer; pyridoxal 5'-phosphate at 30℃; for 0.5h; relative rate of CO2 evolution by aromatic L-amino acid decarboxylase from Micrococcus percitreus;
With isopropyl β-D-thiogalactoside; L-tryptophan decarboxylase in recombinant Escherichia coli at 28℃;
5-hydroxy-Nb-methoxycarbonyltryptamine
77549-09-8

5-hydroxy-Nb-methoxycarbonyltryptamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With sodium hydroxide In methanol Heating;73%
With sodium hydroxide In methanol for 4h; Heating;73%
2-(5-methoxyindol-3-yl)ethylamine
608-07-1

2-(5-methoxyindol-3-yl)ethylamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With boron tribromide In dichloromethane at 20℃;65%
With aluminium trichloride; benzene
5-benzyloxytryptamine
20776-45-8

5-benzyloxytryptamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With methanol; palladium on activated charcoal Hydrogenation;
With palladium on activated charcoal; ethanol; water Hydrogenation;
With methanol; Pd-BaSO4 Hydrogenation;
5-benzyloxy-3-(2-nitro-ethyl)-indole
93331-75-0

5-benzyloxy-3-(2-nitro-ethyl)-indole

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With platinum Hydrogenation;
With palladium on activated charcoal Hydrogenation;
[2-(5-benzyloxy-indol-3-yl)-ethyl]-carbamic acid benzyl ester
55895-70-0

[2-(5-benzyloxy-indol-3-yl)-ethyl]-carbamic acid benzyl ester

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With hydrogenchloride; palladium on activated charcoal; ethanol Hydrogenation.und Wasser;
tryptamine
61-54-1

tryptamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
biotransformation by cell cultures of Peganum harmala;
With CYP71P1; NADPH; NADPH-P450 reductase at 30℃; for 0.166667h; pH=7.25; Kinetics; aq. phosphate buffer; Enzymatic reaction;
tryptamine hydochloride
343-94-2

tryptamine hydochloride

A

7-Hydroxytryptamine
15700-23-9

7-Hydroxytryptamine

B

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

C

6-hydroxytryptamine
443-31-2

6-hydroxytryptamine

D

4-Hydroxytryptamine
570-14-9

4-Hydroxytryptamine

Conditions
ConditionsYield
With sodium hydroxide; dihydrogen peroxide; ascorbic acid 1.) H2O, 2.) phosphate buffer (pH= 7.2, 0.1 M), 22 deg C, 2.5 min; Multistep reaction. Title compound not separated from byproducts;
N-Cbz-5-hydroxytryptamine
53157-50-9

N-Cbz-5-hydroxytryptamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In methanol Yield given;
5-hydroxytryptophan
56-69-9

5-hydroxytryptophan

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With pyridoxal 5'-phosphate mammalian aromatic L-amino acid decarboxylase;
With Papaver somniferum tyrosine decarboxylase S372G mutant In aq. phosphate buffer at 25℃; pH=7.5; Kinetics; Reagent/catalyst; Enzymatic reaction;
2-<3-amino-1-aminomethyl-propyl>-hydroquinone dihydriodide

2-<3-amino-1-aminomethyl-propyl>-hydroquinone dihydriodide

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
With water; sodium hydrogencarbonate; potassium hexacyanoferrate(III)
2-(1-benzyl-5-methoxy-1H-indol-3-yl)ethylamine
40619-73-6

2-(1-benzyl-5-methoxy-1H-indol-3-yl)ethylamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 66 percent / Na / tetrahydrofuran; liquid ammonia / 1.5 h / -33 °C
2: 65 percent / BBr3 / CH2Cl2 / 20 °C
View Scheme
1-benzyl-5-methoxy-1H-indole-3-acetamide
93879-42-6

1-benzyl-5-methoxy-1H-indole-3-acetamide

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 60.5 percent / LiAlH4 / diethyl ether / 48 h / Heating
2: 66 percent / Na / tetrahydrofuran; liquid ammonia / 1.5 h / -33 °C
3: 65 percent / BBr3 / CH2Cl2 / 20 °C
View Scheme
methyl 1-benzyl-5-methoxy-1H-indole-3-acetate
419569-93-0

methyl 1-benzyl-5-methoxy-1H-indole-3-acetate

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 83 percent / NH3 / methanol / 192 h / 20 °C
2: 60.5 percent / LiAlH4 / diethyl ether / 48 h / Heating
3: 66 percent / Na / tetrahydrofuran; liquid ammonia / 1.5 h / -33 °C
4: 65 percent / BBr3 / CH2Cl2 / 20 °C
View Scheme
1-formyl-5-hydroxy-N-methoxycarbonyltryptamine
185987-04-6

1-formyl-5-hydroxy-N-methoxycarbonyltryptamine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 76 percent / 2N NaOH / methanol
2: 73 percent / 10percent NaOH / methanol / Heating
View Scheme
(2-indol-3-yl-ethyl)-carbamic acid benzyl ester
38750-13-9

(2-indol-3-yl-ethyl)-carbamic acid benzyl ester

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 1.) Pb(OAc)4; 2.) Zn powder / 1.) CF3COOH, CH2Cl2
2: H2 / 5percent Pd-C / methanol
View Scheme
5-benzyloxy-1H-indole
1215-59-4

5-benzyloxy-1H-indole

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: acetic acid; dioxane
2: NaCN; aqueous ethanol
3: LiAlH4; diethyl ether
4: palladium/charcoal; ethanol / Hydrogenation
View Scheme
Multi-step reaction with 4 steps
1: phosphoryl chloride / und anschliessenden Hydrolysieren mit wss.Natronlauge bzw. wss.Natriumcarbonat-Loesung
2: ammonium acetate
3: LiAlH4; diethyl ether
4: methanol; palladium/charcoal / Hydrogenation
View Scheme
Multi-step reaction with 4 steps
1: phosphoryl chloride / und anschliessenden Hydrolysieren mit wss.Natronlauge bzw. wss.Natriumcarbonat-Loesung
2: benzylamine
3: LiAlH4; THF
4: palladium/charcoal; ethanol; water / Hydrogenation
View Scheme
NSC 73391
2436-15-9

NSC 73391

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: LiAlH4; diethyl ether
2: palladium/charcoal; ethanol / Hydrogenation
View Scheme
5-Benzyloxy-2,ω-dinitro-styrol
92438-11-4

5-Benzyloxy-2,ω-dinitro-styrol

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: ethanol; acetic acid
2: acetic acid; dioxane
3: NaCN; aqueous ethanol
4: LiAlH4; diethyl ether
5: palladium/charcoal; ethanol / Hydrogenation
View Scheme
5-benzyloxygramine
1453-97-0

5-benzyloxygramine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: NaCN; aqueous ethanol
2: LiAlH4; diethyl ether
3: palladium/charcoal; ethanol / Hydrogenation
View Scheme
Multi-step reaction with 3 steps
1: NaCN; aqueous ethanol
2: LiAlH4; diethyl ether
3: platinum/charcoal; methanol / Hydrogenation
View Scheme
5-benzyloxyindole-3-acetamide
5933-28-8

5-benzyloxyindole-3-acetamide

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: LiAlH4; diethyl ether
2: palladium/charcoal; ethanol / Hydrogenation
View Scheme
Multi-step reaction with 2 steps
1: LiAlH4; diethyl ether
2: platinum/charcoal; methanol / Hydrogenation
View Scheme
(5-benzyloxy-indol-3-yl)-glyoxylic acid amide
22424-62-0

(5-benzyloxy-indol-3-yl)-glyoxylic acid amide

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: LiAlH4; diethyl ether; THF
2: palladium/BaSO4; methanol / Hydrogenation
View Scheme
2-(5-(benzyloxy)-1H-indol-3-yl)-2-oxoacetyl chloride
22424-61-9

2-(5-(benzyloxy)-1H-indol-3-yl)-2-oxoacetyl chloride

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: aqueous NH3 <28percent >
2: LiAlH4; diethyl ether; THF
3: palladium/BaSO4; methanol / Hydrogenation
View Scheme
3-(5-benzyloxy-indol-3-yl)-propionic acid
7394-76-5

3-(5-benzyloxy-indol-3-yl)-propionic acid

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: methanol. HCl
2: ethanol; N2H4+H2O
3: benzene; NaNO2; aqueous acetic acid / Erwaermen des Reaktionsprodukts in Benzol mit Benzylalkohol
4: palladium/charcoal; HCl; ethanol / Hydrogenation.und Wasser
View Scheme
3-(5-benzyloxy-indol-3-yl)-propionic acid methyl ester
101890-43-1

3-(5-benzyloxy-indol-3-yl)-propionic acid methyl ester

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: ethanol; N2H4+H2O
2: benzene; NaNO2; aqueous acetic acid / Erwaermen des Reaktionsprodukts in Benzol mit Benzylalkohol
3: palladium/charcoal; HCl; ethanol / Hydrogenation.und Wasser
View Scheme
3-(5-benzyloxy-indol-3-yl)-propionic acid hydrazide
101783-03-3

3-(5-benzyloxy-indol-3-yl)-propionic acid hydrazide

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: benzene; NaNO2; aqueous acetic acid / Erwaermen des Reaktionsprodukts in Benzol mit Benzylalkohol
2: palladium/charcoal; HCl; ethanol / Hydrogenation.und Wasser
View Scheme
5-benzyloxy-3-(2-carboxy-ethyl)-indole-2-carboxylic acid
7358-97-6

5-benzyloxy-3-(2-carboxy-ethyl)-indole-2-carboxylic acid

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: tetralin
2: methanol. HCl
3: ethanol; N2H4+H2O
4: benzene; NaNO2; aqueous acetic acid / Erwaermen des Reaktionsprodukts in Benzol mit Benzylalkohol
5: palladium/charcoal; HCl; ethanol / Hydrogenation.und Wasser
View Scheme
5-benzyloxyindole-3-carboxaldehyde
6953-22-6

5-benzyloxyindole-3-carboxaldehyde

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: ammonium acetate
2: LiAlH4; diethyl ether
3: methanol; palladium/charcoal / Hydrogenation
View Scheme
Multi-step reaction with 3 steps
1: benzylamine
2: LiAlH4; THF
3: palladium/charcoal; ethanol; water / Hydrogenation
View Scheme
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

(E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid
1135-24-6

(E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid

(2E)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide
68573-23-9

(2E)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide99%
Stage #1: (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol With triethylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; Inert atmosphere;
57%
Stage #1: 3-(2-aminoethyl)-1H-indol-5-ol; (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid With pyridine; dicyclohexyl-carbodiimide at 20℃; for 24h;
Stage #2: With potassium hydroxide In methanol at 20℃; for 4h;
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Trifluoroacetaldehyde ethyl hemiacetal
433-27-2

Trifluoroacetaldehyde ethyl hemiacetal

6-hydroxy-1-trifluoromethyl-1,2,3,4-tetrahydro-9H-pyrido<3,4-b>indole
126260-67-1

6-hydroxy-1-trifluoromethyl-1,2,3,4-tetrahydro-9H-pyrido<3,4-b>indole

Conditions
ConditionsYield
at 110 - 120℃; for 5h;98.8%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

methyl chloroformate
79-22-1

methyl chloroformate

5-hydroxy-Nb-methoxycarbonyltryptamine
77549-09-8

5-hydroxy-Nb-methoxycarbonyltryptamine

Conditions
ConditionsYield
With pyridine In N,N-dimethyl-formamide at 0 - 20℃; for 1.5h;94%
(2R,4R)-2-[2-[4-fluoro-2-[2-(4-fluoro-3-methoxyphenyl)ethyl]phenoxy]ethyl]-4-hydroxy-1-methylpyrrolidine
195299-77-5

(2R,4R)-2-[2-[4-fluoro-2-[2-(4-fluoro-3-methoxyphenyl)ethyl]phenoxy]ethyl]-4-hydroxy-1-methylpyrrolidine

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

lauric anhydride
645-66-9

lauric anhydride

(2R,4R)-2-[2-[4-fluoro-2-[2-(4-fluoro-3-methoxyphenyl)ethyl]phenoxy]ethyl]-4-lauroyloxy-1-methylpyrrolidine

(2R,4R)-2-[2-[4-fluoro-2-[2-(4-fluoro-3-methoxyphenyl)ethyl]phenoxy]ethyl]-4-lauroyloxy-1-methylpyrrolidine

Conditions
ConditionsYield
With pyridine; dmap91%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

(Z)-2-hydroxy-3-phenyl-acrylic acid
5801-57-0, 52178-60-6

(Z)-2-hydroxy-3-phenyl-acrylic acid

1-benzyl-1,2,3,4-tetrahydro-8-hydroxy-β-carboline-1-carboxylic acid
17994-22-8

1-benzyl-1,2,3,4-tetrahydro-8-hydroxy-β-carboline-1-carboxylic acid

Conditions
ConditionsYield
In ethanol for 48h;90%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

2,2-Dichloropropionic acid
75-99-0

2,2-Dichloropropionic acid

C13H14Cl2N2O2
1388185-92-9

C13H14Cl2N2O2

Conditions
ConditionsYield
With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 0 - 20℃; for 24h;89%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

Arachidic acid
506-30-9

Arachidic acid

N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)icosanamide
21249-34-3

N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)icosanamide

Conditions
ConditionsYield
With benzotriazol-1-ol; triethylamine In N,N-dimethyl-formamide at 20℃; Reagent/catalyst; Solvent;88%
diethylenetriaminepentaacetic dianhydride
23911-26-4

diethylenetriaminepentaacetic dianhydride

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

bis-5-hydroxytriptamide-DPTA
875429-83-7

bis-5-hydroxytriptamide-DPTA

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h;87%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 48h;58%
Stage #1: diethylenetriaminepentaacetic dianhydride; 3-(2-aminoethyl)-1H-indol-5-ol With pyridine; ascorbic acid In N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: With water
vinyl acetate
108-05-4

vinyl acetate

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

N-acetyl-5-hydroxytryptamine
1210-83-9

N-acetyl-5-hydroxytryptamine

Conditions
ConditionsYield
With agarose immobilized acetyltransferase from Mycobacterium smegmatis (MsAcT) In aq. phosphate buffer; dimethyl sulfoxide at 25℃; under 760.051 Torr; for 0.0833333h; pH=8.0; Flow reactor; Enzymatic reaction; chemoselective reaction;85%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

benzyl chloroformate
501-53-1

benzyl chloroformate

N-Cbz-5-hydroxytryptamine
53157-50-9

N-Cbz-5-hydroxytryptamine

Conditions
ConditionsYield
With sodium carbonate In water for 6h; Ambient temperature;84%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

<5,6,8,9,11,12,14,15-3H8>arachidonic acid
66753-05-7

<5,6,8,9,11,12,14,15-3H8>arachidonic acid

N-[5,6,8,9,11,12,14,15-3H8]arachidonoyl5-hydroxytryptamine

N-[5,6,8,9,11,12,14,15-3H8]arachidonoyl5-hydroxytryptamine

Conditions
ConditionsYield
Stage #1: <5,6,8,9,11,12,14,15-3H8>arachidonic acid With triethylamine; isobutyl chloroformate In acetonitrile at 23℃; for 2h;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol In N,N-dimethyl-formamide at 23℃; for 20h;
83%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

p-Coumaric Acid
7400-08-0

p-Coumaric Acid

N-p-coumaroylserotonin
68573-24-0

N-p-coumaroylserotonin

Conditions
ConditionsYield
Stage #1: p-Coumaric Acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol With triethylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; Inert atmosphere;
82%
With benzotriazol-1-ol; dicyclohexyl-carbodiimide79%
Stage #1: 3-(2-aminoethyl)-1H-indol-5-ol; p-Coumaric Acid With pyridine; dicyclohexyl-carbodiimide at 20℃; for 24h;
Stage #2: With potassium hydroxide In methanol at 20℃; for 4h;
0.14 mmol
(Z)-9-octadecenoyl chloride
112-77-6

(Z)-9-octadecenoyl chloride

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

(Z)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-9-octadecenamide
1002100-44-8

(Z)-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-9-octadecenamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 5h; Cooling with ice;82%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

(S)-2-((tert-butoxycarbonyl)amino)-3-(5-hydroxy-1H-indol-3-yl)propanoic acid
119768-45-5

(S)-2-((tert-butoxycarbonyl)amino)-3-(5-hydroxy-1H-indol-3-yl)propanoic acid

(S)-tert-butyl (3-(5-hydroxy-1H-indol-3-yl)-1-((2-(5-hydroxy-1H-indol-3-yl)ethyl)amino)-1-oxopropan-2-yl)carbamate

(S)-tert-butyl (3-(5-hydroxy-1H-indol-3-yl)-1-((2-(5-hydroxy-1H-indol-3-yl)ethyl)amino)-1-oxopropan-2-yl)carbamate

Conditions
ConditionsYield
Stage #1: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-hydroxy-1H-indol-3-yl)propanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide for 0.166667h;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol In N,N-dimethyl-formamide for 2h;
82%
Stage #1: (S)-2-((tert-butoxycarbonyl)amino)-3-(5-hydroxy-1H-indol-3-yl)propanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; for 0.166667h;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol In N,N-dimethyl-formamide at 20℃; for 2h;
390 mg
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

2-(phenylamino)benzoic acid
91-40-7

2-(phenylamino)benzoic acid

N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)-2-(phenylamino)benzamide

N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)-2-(phenylamino)benzamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 8h;75%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

mefenamic Acid
61-68-7

mefenamic Acid

2-((2,3-dimethylphenyl)amino)-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)benzamide

2-((2,3-dimethylphenyl)amino)-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)benzamide

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 8h;75%
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 20℃; for 8h;75%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

piperic acid chloride
4711-72-2

piperic acid chloride

N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-5-(3,4-methylenedioxyphenyl)-2E,4E-pentadienamide

N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-5-(3,4-methylenedioxyphenyl)-2E,4E-pentadienamide

Conditions
ConditionsYield
With triethylamine at 20℃; for 5h; Cooling with ice;70%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

2,5,7,8-tetramethyl-6-(oxiran-2-ylmethoxy)-2-(4,8,12-trimethyltridecyl)chroman
153821-44-4

2,5,7,8-tetramethyl-6-(oxiran-2-ylmethoxy)-2-(4,8,12-trimethyltridecyl)chroman

C42H66N2O4

C42H66N2O4

Conditions
ConditionsYield
Stage #1: 3-(2-aminoethyl)-1H-indol-5-ol at -10℃; for 1h; Alkaline conditions;
Stage #2: 2,5,7,8-tetramethyl-6-(oxiran-2-ylmethoxy)-2-(4,8,12-trimethyltridecyl)chroman In dichloromethane at -10℃; for 12h; regioselective reaction;
70%
isoalantolactone
470-17-7

isoalantolactone

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

(3aR,8aR,9aR)-3-{[2-(5-hydroxy-1H-indol-3-yl)ethylamino]methyl}-8a-methyl-5-methylidene-decahydronaphtho[2,3-b]furan-2-one hydrochloride
1353868-49-1

(3aR,8aR,9aR)-3-{[2-(5-hydroxy-1H-indol-3-yl)ethylamino]methyl}-8a-methyl-5-methylidene-decahydronaphtho[2,3-b]furan-2-one hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In methanol at 20℃; Michael type reaction; stereospecific reaction;68%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

N,N'-bis-Boc-S-methyl-isothiourea
322474-21-5

N,N'-bis-Boc-S-methyl-isothiourea

N',N''-bis(tert-butoxycarbonyl)-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)guanidine

N',N''-bis(tert-butoxycarbonyl)-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)guanidine

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 0 - 20℃;67%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

alepterolic acid

alepterolic acid

(E)-N-(2-[5-hydroxy-1H-indol-3-yl]ethyl)-5-([1R,4aS,6R,8aS]-6-hydroxy-5,5,8a-trimethyl-2-methylenedecahydronaphthalene-1-yl)-3-methylpent-2-enamide

(E)-N-(2-[5-hydroxy-1H-indol-3-yl]ethyl)-5-([1R,4aS,6R,8aS]-6-hydroxy-5,5,8a-trimethyl-2-methylenedecahydronaphthalene-1-yl)-3-methylpent-2-enamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 20℃;65%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

C18H16O7
1448991-74-9

C18H16O7

Dimethyl-3-(2-hydroxybenzoyl)-9-hydroxy-6,7,12,12b-tetrahydroindolo[2,3-a]quinolizine-1,12b-dicarboxylate
1355043-50-3

Dimethyl-3-(2-hydroxybenzoyl)-9-hydroxy-6,7,12,12b-tetrahydroindolo[2,3-a]quinolizine-1,12b-dicarboxylate

Conditions
ConditionsYield
Stage #1: 3-(2-aminoethyl)-1H-indol-5-ol; C18H16O7 With trimethyl orthoformate In dichloromethane at 20℃; Inert atmosphere;
Stage #2: With trifluoroacetic acid In dichloromethane at 20℃; Inert atmosphere;
64%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

2-nitrobenzenesulfenyl chloride
7669-54-7

2-nitrobenzenesulfenyl chloride

3-(2-Amino-ethyl)-2-(2-nitro-phenylsulfanyl)-1H-indol-5-ol
102250-06-6

3-(2-Amino-ethyl)-2-(2-nitro-phenylsulfanyl)-1H-indol-5-ol

Conditions
ConditionsYield
In acetic acid at 0℃; for 3h;63%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

1-acetyl-2-methylsulfanyl-4-imidazolidinone
291519-12-5

1-acetyl-2-methylsulfanyl-4-imidazolidinone

1-acetyl-2-[2-(5-hydroxy-1H-indol-3-yl)ethylamino]-4,5-dihydroimidazol-4-one

1-acetyl-2-[2-(5-hydroxy-1H-indol-3-yl)ethylamino]-4,5-dihydroimidazol-4-one

Conditions
ConditionsYield
In ethanol for 96h; Reflux;60%
3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

2,2-dichloro-3-(6-methyl-2-oxo-2H-chromen-4-yl)propanoic acid

2,2-dichloro-3-(6-methyl-2-oxo-2H-chromen-4-yl)propanoic acid

2,2-dichloro-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)-3-(6-methyl-2-oxo-2H-chromen-4-yl)propanamide

2,2-dichloro-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)-3-(6-methyl-2-oxo-2H-chromen-4-yl)propanamide

Conditions
ConditionsYield
Stage #1: 2,2-dichloro-3-(6-methyl-2-oxo-2H-chromen-4-yl)propanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In N,N-dimethyl-formamide for 0.333333h; Inert atmosphere;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol In N,N-dimethyl-formamide at 20℃; for 18h; Inert atmosphere;
60%
(-)-(S)-3-(benzyloxycarbonylamino-methyl)-5-methyl-hexanoic acid
949890-75-9

(-)-(S)-3-(benzyloxycarbonylamino-methyl)-5-methyl-hexanoic acid

3-(2-aminoethyl)-1H-indol-5-ol
50-67-9

3-(2-aminoethyl)-1H-indol-5-ol

C26H33N3O4
1224700-50-8

C26H33N3O4

Conditions
ConditionsYield
Stage #1: (-)-(S)-3-(benzyloxycarbonylamino-methyl)-5-methyl-hexanoic acid With N-ethylmorpholine;; isobutyl chloroformate In tetrahydrofuran at -15℃; for 0.0333333h;
Stage #2: 3-(2-aminoethyl)-1H-indol-5-ol In tetrahydrofuran; water at -15 - 20℃; for 24.1667h;
56%

50-67-9Relevant articles and documents

-

Gryglewski et al.

, p. 471,472 (1966)

-

Studies of enzyme-mediated reactions. Part 161. Stereochemical course of the formation of 5-hydroxytryptamine (serotonin) by decarboxylation of (2S)-5-hydroxytryptophan with the aromatic L-amino acid decarboxylase (E.C. 4.1.1.28) from Hog Kidney

Battersby,Scott,Staunton

, p. 4685 - 4696 (1990)

-

Rice histone deacetylase 10 and Arabidopsis histone deacetylase 14 genes encode N-acetylserotonin deacetylase, which catalyzes conversion of N-acetylserotonin into serotonin, a reverse reaction for melatonin biosynthesis in plants

Lee, Kyungjin,Lee, Hyoung Yool,Back, Kyoungwhan

, (2018)

In plants, melatonin production is strictly regulated, unlike the production of its precursor, serotonin, which is highly inducible in response to stimuli, such as senescence and pathogen exposure. Exogenous serotonin treatment does not greatly induce the production of N-acetylserotonin (NAS) and melatonin in plants, which suggests the possible existence of one or more regulatory genes in the pathway for the biosynthesis of melatonin from serotonin. In this report, we found that NAS was rapidly and abundantly converted into serotonin in rice seedlings, indicating the presence of an N-acetylserotonin deacetylase (ASDAC). To clone the putative ASDAC gene, we screened 4 genes that were known as histone deacetylase (HDAC) genes, but encoded proteins targeted into chloroplasts or mitochondria rather than nuclei. Of 4 recombinant Escherichia coli strains expressing these genes, one E.?coli strain expressing the rice HDAC10 gene was found to be capable of producing serotonin in response to treatment with NAS. The recombinant purified rice HDAC10 (OsHDAC10) protein exhibited ASDAC enzyme activity toward NAS, N-acetyltyramine (NAT), N-acetyltryptamine, and melatonin, with the highest ASDAC activity for NAT. In addition, its Arabidopsis ortholog, AtHDAC14, showed similar ASDAC activity to that of OsHDAC10. Both OsHDAC10 and AtHDAC14 were found to be expressed in chloroplasts. Phylogenetic analysis indicated that ASDAC homologs were present in archaea, but not in cyanobacteria, which differs from the distribution of serotonin N-acetyltransferase (SNAT). This suggests that SNAT and ASDAC may have evolved differently from ancestral eukaryotic cells.

-

Petrova et al.

, (1971)

-

Sekiguchi lesion gene encodes a cytochrome P450 monooxygenase that catalyzes conversion of tryptamine to serotonin in rice

Fujiwara, Tadashi,Maisonneuve, Sylvie,Isshiki, Masayuki,Mizutani, Masaharu,Chen, Letian,Ling Wong, Hann,Kawasaki, Tsutomu,Shimamoto, Ko

, p. 11308 - 11313 (2010)

Serotonin is a well known neurotransmitter in mammals and plays an important role in various mental functions in humans. In plants, the serotonin biosynthesis pathway and its function are not well understood. The rice sekiguchi lesion (sl) mutants accumulate tryptamine, a candidate substrate for serotonin biosynthesis. We isolated the SL gene by map-based cloning and found that it encodes CYP71P1 in a cytochrome P450 monooxygenase family. A recombinant SL protein exhibited tryptamine 5-hydroxylase enzyme activity and catalyzed the conversion of tryptamine to serotonin. This pathway is novel and has not been reported in mammals. Expression of SL was induced by the N- acetylchitooligosaccharide (chitin) elicitor and by infection with Magnaporthe grisea, a causal agent for rice blast disease. Exogenously applied serotonin induced defense gene expression and cell death in rice suspension cultures and increased resistance to rice blast infection in plants. We also found that serotonin-induced defense gene expression is mediated by the RacGTPase pathway and by the Gα subunit of the heterotrimeric G protein. These results suggest that serotonin plays an important role in rice innate immunity.

The Study of Stability of Proline-Containing Derivatives of Dopamine and Serotonin in the Biological Media in Vitro Experiments

Andreeva, L. A.,Myasoedov, N. F.,Nagaev, I. Yu.,Shevchenko, K. V.,Shevchenko, V. P.

, p. 150 - 158 (2020/05/28)

Abstract—: The peptides Boc-Gly-Pro-DP, Z-Gly-Pro-DP, LA-Gly-Pro-DP, Boc-Gly-Pro-Srt, Z-Gly-Pro-Srt have been synthesized for the first time. The study of their stability in the presence of leucine aminopeptidase, carboxypeptidase Y, carboxypeptidase B, and proline endopeptidase (PEP) has shown that the synthesized peptides are stable in the presence of aminopeptidases and carboxypeptidases. In the presence of PEP, dopamine (DP) and serotonin (Srt) have been cleaved from these substances. Thus, the originally synthesized proline derivatives of Srt and DP may be considered as the resources, from which Srt and DP can be gradually released. This creates the possibility of a prolonged action of these biologically active compounds on cells and, consequently, on the whole body.

Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions

Blei, Felix,Baldeweg, Florian,Fricke, Janis,Hoffmeister, Dirk

, p. 10028 - 10031 (2018/07/29)

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the main alkaloid of the fungal genus Psilocybe, the so-called “magic mushrooms.” The pharmaceutical interest in this psychotropic natural product as a future medication to treat depression and anxiety is strongly re-emerging. Here, we present an enhanced enzymatic route of psilocybin production by adding TrpB, the tryptophan synthase of the mushroom Psilocybe cubensis, to the reaction. We capitalized on its substrate flexibility and show psilocybin formation from 4-hydroxyindole and l-serine, which are less cost-intensive substrates, compared to the previous method. Furthermore, we show enzymatic production of 7-phosphoryloxytryptamine (isonorbaeocystin), a non-natural congener of the Psilocybe alkaloid norbaeocystin (4-phosphoryloxytryptamine), and of serotonin (5-hydroxytryptamine) by means of the same in vitro approach.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50-67-9